Market Data 
Markets
Replies to post #122470 on Biotech Values
06/27/11 10:44 PM
HALO—Unfortunately, management has seemed to highlight this [insulin] program for quite some time and shareholders fortunes may be tied to their ability to consummate a deal by Q1 '11 (their target).
"We are going to make a data-driven decision," he said, explaining that Halozyme is weighing whether to license its technology to makers of existing insulins, partner with makers of diabetes drugs who do not currently have an insulin product, market its own product with insulin pumps or all of the above.
AI
